Alaunos Therapeutics settles unpaid invoices with MD Anderson for $285,055

Alaunos Therapeutics, Inc.

Settlement resolves disputes over $285,055 in unpaid invoices under 2019 R&D agreement with MD Anderson.
Alaunos to pay in six installments: $142,528 by Dec 30, 2025, then five monthly payments of $28,506 through May 30, 2026.
Mutual general releases exchanged for claims related to unpaid invoices; ongoing protocol 2006-0676 excluded.
CEO Holger Weis signed agreement on Dec 15, 2025; effective date Dec 17, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Alaunos Therapeutics, Inc. entered into Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center valued at $285,055 (effective 2025-12-17).

Action: entry
Agreement: settlement
Counterparty: The University of Texas M.D. Anderson Cancer Center
Value: $285,055
Effective: 2025-12-17

Exact text from the filing

On December 17, 2025, Alaunos Therapeutics, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) resolving all disputes related to unpaid invoices under the 2019 Research and Development Agreement.

View on SEC.gov

Browse all material agreements →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-331147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.